Chloroquine Levels in Blood During Chronic Treatment of Patients with Rheumatoid Arthritis

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1992 Jan 1

PMID 1307690

Citations 43

Authors

P Augustijns

P Geusens

N Verbeke

Affiliations

Soon will be listed here.

Abstract

Blood levels of racemic chloroquine and its main metabolites desethylchloroquine and bisdesethylchloroquine were measured in 29 patients treated chronically for rheumatoid arthritis. In six patients, the concentrations were followed during a one day dosage interval. There was considerable intersubject variability in the steady state blood concentrations of chloroquine (range 36.6 to 3895 ng.ml-1) and its two main biotransformation products; the latter represented, respectively, 47.7% and 12.9% of the concentration of chloroquine. This finding shows the need for further studies in view of the known toxic effects of chloroquine and the inevitable accumulation due to the exceptionally long residence time of the compound and its metabolites. The main requirement, which has not yet been met, for adding chloroquine to the list of drugs for which therapeutic drug monitoring is useful, is the lack of information about its mechanism of action, and consequently the dose-effect relationships of its therapeutic and toxic actions. Regular ophthalmic examination, in particular, is strongly recommended. The relatively high concentrations of desethylchloroquine and bisdesethylchloroquine found during chronic treatment show the need for more information about the therapeutic value and adverse effects of the metabolites.

Citing Articles

Mechanisms Underlying the Effects of Chloroquine on Red Blood Cells Metabolism.

Russo A, Patane G, Putaggio S, Lombardo G, Ficarra S, Barreca D Int J Mol Sci. 2024; 25(12).

PMID: 38928131 PMC: 11203553. DOI: 10.3390/ijms25126424.

Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease.

Prinz J, Maffulli N, Fuest M, Walter P, Hildebrand F, Migliorini F Diseases. 2023; 11(2).

PMID: 37366873 PMC: 10297605. DOI: 10.3390/diseases11020085.

Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer.

Niemann B, Puleo A, Stout C, Markel J, Boone B Pharmaceutics. 2022; 14(12).

PMID: 36559044 PMC: 9787624. DOI: 10.3390/pharmaceutics14122551.

Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.

Calvo-Alvarez E, Dolci M, Perego F, Signorini L, Parapini S, DAlessandro S Microorganisms. 2022; 10(7).

PMID: 35889004 PMC: 9320270. DOI: 10.3390/microorganisms10071284.

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.

Cocco S, Leone A, Roca M, Lombardi R, Piezzo M, Caputo R J Transl Med. 2022; 20(1):290.

PMID: 35761360 PMC: 9235112. DOI: 10.1186/s12967-022-03462-z.

References

Essien E, Ette E, THOMAS W, Brown-Awala E . Chloroquine disposition in hypersensitive and non-hypersensitive subjects and its significance in chloroquine-induced pruritus. Eur J Drug Metab Pharmacokinet. 1989; 14(1):71-7. DOI: 10.1007/BF03190844. View

Ofori-Adjei D, Ericsson O, Lindstrom B, Sjoqvist F . Protein binding of chloroquine enantiomers and desethylchloroquine. Br J Clin Pharmacol. 1986; 22(3):356-8. PMC: 1401130. DOI: 10.1111/j.1365-2125.1986.tb02900.x. View

LAAKSONEN A, Koskiahde V, JUVA K . Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol. 1974; 3(2):103-8. DOI: 10.3109/03009747409115809. View

Walker O, Birkett D, Alvan G, Gustafsson L, Sjoqvist F . Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol. 1983; 15(3):375-7. PMC: 1427768. DOI: 10.1111/j.1365-2125.1983.tb01513.x. View

Rynes R . Antimalarial treatment of rheumatoid arthritis: 1985 status. J Rheumatol. 1985; 12(4):657-9. View

Wollheim F, Hanson A, LAURELL C . Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels. Scand J Rheumatol. 1978; 7(3):171-6. DOI: 10.3109/03009747809095649. View

MacKenzie A . Antimalarial drugs for rheumatoid arthritis. Am J Med. 1983; 75(6A):48-58. DOI: 10.1016/0002-9343(83)90474-6. View

Frisk-Holmberg M, Bergqvist Y . Steady state disposition of chloroquine in patients with rheumatoid disease. Eur J Clin Pharmacol. 1983; 24(6):837-9. DOI: 10.1007/BF00607097. View

Maksymowych W, Russell A . Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum. 1987; 16(3):206-21. DOI: 10.1016/0049-0172(87)90023-0. View

10.

Rothfield N . Efficacy of antimalarials in systemic lupus erythematosus. Am J Med. 1988; 85(4A):53-6. DOI: 10.1016/0002-9343(88)90363-4. View

11.

Gustafsson L, Walker O, Alvan G, BEERMANN B, Estevez F, GLEISNER L . Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983; 15(4):471-9. PMC: 1427807. DOI: 10.1111/j.1365-2125.1983.tb01532.x. View

12.

TITUS E . Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit. 1989; 11(4):369-79. View

13.

Edwards G, Looareesuwan S, Davies A, Wattanagoon Y, Phillips R, Warrell D . Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol. 1988; 25(4):477-85. PMC: 1387810. DOI: 10.1111/j.1365-2125.1988.tb03332.x. View

14.

Bellamy N, Brooks P . Current practice in antimalarial drug prescribing in rheumatoid arthritis. J Rheumatol. 1986; 13(3):551-5. View

15.

Essien E, Ette E . Effects of chloroquine and didesethylchloroquine on rabbit myocardium and mitochondria. J Pharm Pharmacol. 1986; 38(7):543-6. DOI: 10.1111/j.2042-7158.1986.tb04635.x. View